Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

One of the largest biotech companies in the country has filed a lawsuit claiming improper building practices led to millions in damages at one of its new manufacturing facilities. Moderna is ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market conditions ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close. On Wednesday, the Advisory Committee on Immunization Practices (ACIP ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...